Gemcitabine HCL Market is expected to reach US$ 629.92 Mn. at a CAGR of 4 during the forecast period 2029.Gemcitabine HCL Market Drivers and Restrains
Gemcitabine is a chemotherapy medication used to treat a number of types of cancer. These cancers include breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, and bladder cancer. It is given by slow injection into a vein. Significant improvement shown by gemcitabine HCL for treatment of cancer has prompted players to invest in the treatment of delivery and combination therapy.To know about the Research Methodology :- Request Free Sample Report The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. This has helped offering a competitive edge to the growth of the gemcitabine HCL market. Favorable governmental policies to develop healthcare infrastructure, research and development are factors expected to propel the gemcitabine HCL market in the near future. Further there is need to improve the existing cancer treatment procedure. The ability of gemcitabine HCL to satisfy several needs and improve efficacy of the current trends is a prominent factor, which is expected to fuel the global gemcitabine HCL market. Use of gemcitabine HCL in treatment of pancreas cancer is another factor offering new growth opportunities to market, as pancreas cancer treatment has always been a stressful for oncologists due to unavailability of efficient drugs and medications. However, there are several side effects of gemcitabine HCL drugs e.g., thrombocytopenia, nausea, vomiting, liver enzyme elevation and flu-like symptoms projected to hinder the growth of the global market.
Gemcitabine HCL Market by key segments
The pancreatic cancer segment held a major market share in 2018, owing to the rise in incidences of pancreatic cancer. The hospital in emerging countries is developing at a significant pace as various regional and national governments are encouraging private players to enter the healthcare services sector.Gemcitabine HCL Market Regional Analysis
North America is at the top in terms of share in Global Gemcitabine HCL Market. Large number of key players in North America focusing on research and developments activities to introduce technologically-advanced with better designs are changing the market in the region. Furthermore, Europe held the second-largest dominant market in 2018. Launch of new products, focus on development of technologically-advanced products by companies, and product approvals are expected to drive the global market during the forecast period. The demand for cost-effective generic cancer drugs is rising, especially in emerging countries such as China, India, and Brazil. This is due to the increase in the incidences of cancer and a surge in the acceptance of generic drugs in the global gemcitabine HCL market. India- and China-based drug manufacturers have a strong presence in the global market. Gemcitabine API manufacturers in India have been investing to comply with U.S. FDA regulations and to win contracts from U.S. based companies and have been filing DMF applications. This is expected to fuel the global market in the coming years. The objective of the report is to present comprehensive analysis of Global Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Gemcitabine HCL Market dynamics, structure by analyzing the market segments, and project the Global Market size. Clear representation of competitive analysis of key players by Gemcitabine HCL Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guideScope of the Global Gemcitabine HCL Market: Inquire before buying
Global Gemcitabine HCL Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US $ 478.68 Mn. Forecast Period 2023 to 2029 CAGR: 4% Market Size in 2029: US $ 629.92 Mn. Segments Covered: by end user Hospital Cancer centers by Type TBranded Generic by Application breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer, bladder cancer Gemcitabine HCL Market, by region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Gemcitabine HCL Market Key Players are:
1. Sun Pharmaceutical Industries 2. Tapi Teva 3. Shilpa Medicare 4. Huachu Industrial 5. Jinkang Pharmaceutical Technology 6. Jierui Pharmaceutical 7. HISUN 8. Teva Pharmaceutical Industries Ltd., 9. Lupin Ltd., 10.Sanofi, 11.Biocon. 12.Dr. Reddy’s Laboratories, 13.Mylan N.V., 14.GlaxoSmithKline plc, 15.AstraZeneca plc. 16.Eli Lilly and Company 17.Pfizer Inc. 18.Cipla Inc. 19.Emcure 20.Accord Healthcare 21.Fresenius Kabi USA Frequently Asked questions 1. What is the market size of the Global Gemcitabine HCL Market in 2022? Ans. The market size Global Market in 2022 was US$ 478.68 Million. 2. What are the different segments of the Global Gemcitabine HCL Market? Ans. The Global Market is divided into End User, Application and Type. 3. What is the study period of this market? Ans. The Global Market will be studied from 2022 to 2029. 4. Which region is expected to hold the highest Global Market share? Ans. The Asia Pacific dominates the market share in the market. 5. What is the Forecast Period of Global Gemcitabine HCL Market? Ans. The Forecast Period of the market is 2023-2029 in the market.
Global Gemcitabine HCL Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Gemcitabine HCL Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Gemcitabine HCL Market Analysis and Forecast 6.1. Global Gemcitabine HCL Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Gemcitabine HCL Market Analysis and Forecast, by End-user 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Gemcitabine HCL Market Value Share Analysis, by End-user 7.4. Global Gemcitabine HCL Market Size (US$ Bn) Forecast, by End-user 7.5. Global Gemcitabine HCL Market Analysis, by End-user 7.6. Global Gemcitabine HCL Market Attractiveness Analysis, by End-user 8. Global Gemcitabine HCL Market Analysis and Forecast, by Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Gemcitabine HCL Market Value Share Analysis, by Type 8.4. Global Gemcitabine HCL Market Size (US$ Bn) Forecast, by Type 8.5. Global Gemcitabine HCL Market Analysis, by Type 8.6. Global Gemcitabine HCL Market Attractiveness Analysis, by Type 9. Global Gemcitabine HCL Market Analysis and Forecast, by Application 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Gemcitabine HCL Market Value Share Analysis, by Application 9.4. Global Gemcitabine HCL Market Size (US$ Bn) Forecast, by Application 9.5. Global Gemcitabine HCL Market Analysis, by Application 9.6. Global Gemcitabine HCL Market Attractiveness Analysis, by Application 10. Global Gemcitabine HCL Market Analysis, by Region 10.1. Global Gemcitabine HCL Market Value Share Analysis, by Region 10.2. Global Gemcitabine HCL Market Size (US$ Bn) Forecast, by Region 10.3. Global Gemcitabine HCL Market Attractiveness Analysis, by Region 11. North America Gemcitabine HCL Market Analysis 11.1. Key Findings 11.2. North America Gemcitabine HCL Market Overview 11.3. North America Gemcitabine HCL Market Value Share Analysis, by End-user 11.4. North America Gemcitabine HCL Market Forecast, by End-user 11.4.1. Hospital 11.4.2. Cancer centers 11.5. North America Gemcitabine HCL Market Value Share Analysis, by Type 11.6. North America Gemcitabine HCL Market Forecast, by Type 11.6.1. Branded 11.6.2. generic 11.7. North America Gemcitabine HCL Market Value Share Analysis, by Application 11.8. North America Gemcitabine HCL Market Forecast, by Application 11.8.1. breast cancer, 11.8.2. ovarian cancer, 11.8.3. non-small cell lung cancer, 11.8.4. pancreatic cancer, 11.8.5. bladder cancer 11.9. North America Gemcitabine HCL Market Value Share Analysis, by Country 11.10. North America Gemcitabine HCL Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Gemcitabine HCL Market Analysis, by Country 11.12. U.S. Gemcitabine HCL Market Forecast, by End-user 11.12.1. Hospital 11.12.2. Cancer centers 11.13. U.S. Gemcitabine HCL Market Forecast, by Type 11.13.1. Branded 11.13.2. generic 11.14. U.S. Gemcitabine HCL Market Forecast, by Application 11.14.1. breast cancer, 11.14.2. ovarian cancer, 11.14.3. non-small cell lung cancer, 11.14.4. pancreatic cancer, 11.14.5. bladder cancer 11.15. Canada Gemcitabine HCL Market Forecast, by End-user 11.15.1. Hospital 11.15.2. Cancer centers 11.16. Steel Canada Gemcitabine HCL Market Forecast, by Type 11.16.1. Branded 11.16.2. generic 11.17. Canada Gemcitabine HCL Market Forecast, by Application 11.17.1. breast cancer, 11.17.2. ovarian cancer, 11.17.3. non-small cell lung cancer, 11.17.4. pancreatic cancer, 11.17.5. bladder cancer 11.18. North America Gemcitabine HCL Market Attractiveness Analysis 11.18.1. By End-user 11.18.2. By Type 11.18.3. By Application 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Gemcitabine HCL Market Analysis 12.1. Key Findings 12.2. Europe Gemcitabine HCL Market Overview 12.3. Europe Gemcitabine HCL Market Value Share Analysis, by End-user 12.4. Europe Gemcitabine HCL Market Forecast, by End-user 12.4.1. Hospital 12.4.2. Cancer centers 12.5. Europe Gemcitabine HCL Market Value Share Analysis, by Type 12.6. Europe Gemcitabine HCL Market Forecast, by Type 12.6.1. Branded 12.6.2. generic 12.7. Europe Gemcitabine HCL Market Value Share Analysis, by Application 12.8. Europe Gemcitabine HCL Market Forecast, by Application 12.8.1. breast cancer, 12.8.2. ovarian cancer, 12.8.3. non-small cell lung cancer, 12.8.4. pancreatic cancer, 12.8.5. bladder cancer 12.9. Europe Gemcitabine HCL Market Value Share Analysis, by Country 12.10. Europe Gemcitabine HCL Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Gemcitabine HCL Market Analysis, by Country 12.12. Germany Gemcitabine HCL Market Forecast, by End-user 12.12.1. Hospital 12.12.2. Cancer centers 12.13. Germany Gemcitabine HCL Market Forecast, by Type 12.13.1. Branded 12.13.2. generic 12.14. Germany Gemcitabine HCL Market Forecast, by Application 12.14.1. breast cancer, 12.14.2. ovarian cancer, 12.14.3. non-small cell lung cancer, 12.14.4. pancreatic cancer, 12.14.5. bladder cancer 12.15. U.K. Gemcitabine HCL Market Forecast, by End-user 12.15.1. Hospital 12.15.2. Cancer centers 12.16. U.K. Gemcitabine HCL Market Forecast, by Type 12.16.1. Branded 12.16.2. generic 12.17. U.K. Gemcitabine HCL Market Forecast, by Application 12.17.1. breast cancer, 12.17.2. ovarian cancer, 12.17.3. non-small cell lung cancer, 12.17.4. pancreatic cancer, 12.17.5. bladder cancer 12.18. France Gemcitabine HCL Market Forecast, by End-user 12.18.1. Hospital 12.18.2. Cancer centers 12.19. France Gemcitabine HCL Market Forecast, by Type 12.19.1. Branded 12.19.2. generic 12.20. France Gemcitabine HCL Market Forecast, by Application 12.20.1. breast cancer, 12.20.2. ovarian cancer, 12.20.3. non-small cell lung cancer, 12.20.4. pancreatic cancer, 12.20.5. bladder cancer 12.21. Italy Gemcitabine HCL Market Forecast, by End-user 12.21.1. Hospital 12.21.2. Cancer centers 12.22. Italy Gemcitabine HCL Market Forecast, by Type 12.22.1. Branded 12.22.2. generic 12.23. Italy Gemcitabine HCL Market Forecast, by Application 12.23.1. breast cancer, 12.23.2. ovarian cancer, 12.23.3. non-small cell lung cancer, 12.23.4. pancreatic cancer, 12.23.5. bladder cancer 12.24. Spain Gemcitabine HCL Market Forecast, by End-user 12.24.1. Hospital 12.24.2. Cancer centers 12.25. Spain Gemcitabine HCL Market Forecast, by Type 12.25.1. Branded 12.25.2. generic 12.26. Spain Gemcitabine HCL Market Forecast, by Application 12.26.1. breast cancer, 12.26.2. ovarian cancer, 12.26.3. non-small cell lung cancer, 12.26.4. pancreatic cancer, 12.26.5. bladder cancer 12.27. Rest of Europe Gemcitabine HCL Market Forecast, by End-user 12.27.1. Hospital 12.27.2. Cancer centers 12.28. Rest of Europe Gemcitabine HCL Market Forecast, by Type 12.28.1. Branded 12.28.2. generic 12.29. Rest Of Europe Gemcitabine HCL Market Forecast, by Application 12.29.1. breast cancer, 12.29.2. ovarian cancer, 12.29.3. non-small cell lung cancer, 12.29.4. pancreatic cancer, 12.29.5. bladder cancer 12.30. Europe Gemcitabine HCL Market Attractiveness Analysis 12.30.1. By End-user 12.30.2. By Type 12.30.3. By Application 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Gemcitabine HCL Market Analysis 13.1. Key Findings 13.2. Asia Pacific Gemcitabine HCL Market Overview 13.3. Asia Pacific Gemcitabine HCL Market Value Share Analysis, by End-user 13.4. Asia Pacific Gemcitabine HCL Market Forecast, by End-user 13.4.1. Hospital 13.4.2. Cancer centers 13.5. Asia Pacific Gemcitabine HCL Market Value Share Analysis, by Type 13.6. Asia Pacific Gemcitabine HCL Market Forecast, by Type 13.6.1. Branded 13.6.2. generic 13.7. Asia Pacific Gemcitabine HCL Market Value Share Analysis, by Application 13.8. Asia Pacific Gemcitabine HCL Market Forecast, by Application 13.8.1. breast cancer, 13.8.2. ovarian cancer, 13.8.3. non-small cell lung cancer, 13.8.4. pancreatic cancer, 13.8.5. bladder cancer 13.9. Asia Pacific Gemcitabine HCL Market Value Share Analysis, by Country 13.10. Asia Pacific Gemcitabine HCL Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Gemcitabine HCL Market Analysis, by Country 13.12. China Gemcitabine HCL Market Forecast, by End-user 13.12.1. Hospital 13.12.2. Cancer centers 13.13. China Gemcitabine HCL Market Forecast, by Type 13.13.1. Branded 13.13.2. generic 13.14. China Gemcitabine HCL Market Forecast, by Application 13.14.1. breast cancer, 13.14.2. ovarian cancer, 13.14.3. non-small cell lung cancer, 13.14.4. pancreatic cancer, 13.14.5. bladder cancer 13.15. India Gemcitabine HCL Market Forecast, by End-user 13.15.1. Hospital 13.15.2. Cancer centers 13.16. India Gemcitabine HCL Market Forecast, by Type 13.16.1. Branded 13.16.2. generic 13.17. India Gemcitabine HCL Market Forecast, by Application 13.17.1. breast cancer, 13.17.2. ovarian cancer, 13.17.3. non-small cell lung cancer, 13.17.4. pancreatic cancer, 13.17.5. bladder cancer 13.18. Japan Gemcitabine HCL Market Forecast, by End-user 13.18.1. Hospital 13.18.2. Cancer centers 13.19. Japan Gemcitabine HCL Market Forecast, by Type 13.19.1. Branded 13.19.2. generic 13.20. Japan Gemcitabine HCL Market Forecast, by Application 13.20.1. breast cancer, 13.20.2. ovarian cancer, 13.20.3. non-small cell lung cancer, 13.20.4. pancreatic cancer, 13.20.5. bladder cancer 13.21. ASEAN Gemcitabine HCL Market Forecast, by End-user 13.21.1. Hospital 13.21.2. Cancer centers 13.22. ASEAN Gemcitabine HCL Market Forecast, by Type 13.22.1. Branded 13.22.2. generic 13.23. ASEAN Gemcitabine HCL Market Forecast, by Application 13.23.1. breast cancer, 13.23.2. ovarian cancer, 13.23.3. non-small cell lung cancer, 13.23.4. pancreatic cancer, 13.23.5. bladder cancer 13.24. Rest of Asia Pacific Gemcitabine HCL Market Forecast, by End-user 13.24.1. Hospital 13.24.2. Cancer centers 13.25. Rest of Asia Pacific Gemcitabine HCL Market Forecast, by Type 13.25.1. Branded 13.25.2. generic 13.26. Rest of Asia Pacific Gemcitabine HCL Market Forecast, by Application 13.26.1. breast cancer, 13.26.2. ovarian cancer, 13.26.3. non-small cell lung cancer, 13.26.4. pancreatic cancer, 13.26.5. bladder cancer 13.27. Asia Pacific Gemcitabine HCL Market Attractiveness Analysis 13.27.1. By End-user 13.27.2. By Type 13.27.3. By Application 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Gemcitabine HCL Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Gemcitabine HCL Market Overview 14.3. Middle East & Africa Gemcitabine HCL Market Value Share Analysis, by End-user 14.4. Middle East & Africa Gemcitabine HCL Market Forecast, by End-user 14.4.1. Hospital 14.4.2. Cancer centers 14.5. Middle East & Africa Gemcitabine HCL Market Value Share Analysis, by Type 14.6. Middle East & Africa Gemcitabine HCL Market Forecast, by Type 14.6.1. Branded 14.6.2. generic 14.7. Middle East & Africa Gemcitabine HCL Market Value Share Analysis, by Application 14.8. Middle East & Africa Gemcitabine HCL Market Forecast, by Application 14.8.1. breast cancer, 14.8.2. ovarian cancer, 14.8.3. non-small cell lung cancer, 14.8.4. pancreatic cancer, 14.8.5. bladder cancer 14.9. Middle East & Africa Gemcitabine HCL Market Value Share Analysis, by Country 14.10. Middle East & Africa Gemcitabine HCL Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Gemcitabine HCL Market Analysis, by Country 14.12. GCC Gemcitabine HCL Market Forecast, by End-user 14.12.1. Hospital 14.12.2. Cancer centers 14.13. GCC Gemcitabine HCL Market Forecast, by Type 14.13.1. Branded 14.13.2. generic 14.14. GCC Gemcitabine HCL Market Forecast, by Application 14.14.1. breast cancer, 14.14.2. ovarian cancer, 14.14.3. non-small cell lung cancer, 14.14.4. pancreatic cancer, 14.14.5. bladder cancer 14.15. South Africa Gemcitabine HCL Market Forecast, by End-user 14.15.1. Hospital 14.15.2. Cancer centers 14.16. South Africa Gemcitabine HCL Market Forecast, by Type 14.16.1. Branded 14.16.2. generic 14.17. South Africa Gemcitabine HCL Market Forecast, by Application 14.17.1. breast cancer, 14.17.2. ovarian cancer, 14.17.3. non-small cell lung cancer, 14.17.4. pancreatic cancer, 14.17.5. bladder cancer 14.18. Rest of Middle East & Africa Gemcitabine HCL Market Forecast, by End-user 14.18.1. Hospital 14.18.2. Cancer centers 14.19. Rest of Middle East & Africa Gemcitabine HCL Market Forecast, by Type 14.19.1. Branded 14.19.2. generic 14.20. Rest of Middle East & Africa Gemcitabine HCL Market Forecast, by Application 14.20.1. breast cancer, 14.20.2. ovarian cancer, 14.20.3. non-small cell lung cancer, 14.20.4. pancreatic cancer, 14.20.5. bladder cancer 14.21. Middle East & Africa Gemcitabine HCL Market Attractiveness Analysis 14.21.1. By End-user 14.21.2. By Type 14.21.3. By Application 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Gemcitabine HCL Market Analysis 15.1. Key Findings 15.2. South America Gemcitabine HCL Market Overview 15.3. South America Gemcitabine HCL Market Value Share Analysis, by End-user 15.4. South America Gemcitabine HCL Market Forecast, by End-user 15.4.1. Hospital 15.4.2. Cancer centers 15.5. South America Gemcitabine HCL Market Value Share Analysis, by Type 15.6. South America Gemcitabine HCL Market Forecast, by Type 15.6.1. Branded 15.6.2. generic 15.7. South America Gemcitabine HCL Market Value Share Analysis, by Application 15.8. South America Gemcitabine HCL Market Forecast, by Application 15.8.1. breast cancer, 15.8.2. ovarian cancer, 15.8.3. non-small cell lung cancer, 15.8.4. pancreatic cancer, 15.8.5. bladder cancer 15.9. South America Gemcitabine HCL Market Value Share Analysis, by Country 15.10. South America Gemcitabine HCL Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Gemcitabine HCL Market Analysis, by Country 15.12. Brazil Gemcitabine HCL Market Forecast, by End-user 15.12.1. Hospital 15.12.2. Cancer centers 15.13. Brazil Gemcitabine HCL Market Forecast, by Type 15.13.1. Branded 15.13.2. generic 15.14. Brazil Gemcitabine HCL Market Forecast, by Application 15.14.1. breast cancer, 15.14.2. ovarian cancer, 15.14.3. non-small cell lung cancer, 15.14.4. pancreatic cancer, 15.14.5. bladder cancer 15.15. Mexico Gemcitabine HCL Market Forecast, by End-user 15.15.1. Hospital 15.15.2. Cancer centers 15.16. Mexico Gemcitabine HCL Market Forecast, by Type 15.16.1. Branded 15.16.2. generic 15.17. Mexico Gemcitabine HCL Market Forecast, by Application 15.17.1. breast cancer, 15.17.2. ovarian cancer, 15.17.3. non-small cell lung cancer, 15.17.4. pancreatic cancer, 15.17.5. bladder cancer 15.18. Rest of South America Gemcitabine HCL Market Forecast, by End-user 15.18.1. Hospital 15.18.2. Cancer centers 15.19. Rest of South America Gemcitabine HCL Market Forecast, by Type 15.19.1. Branded 15.19.2. generic 15.20. Rest of South America Gemcitabine HCL Market Forecast, by Application 15.20.1. breast cancer, 15.20.2. ovarian cancer, 15.20.3. non-small cell lung cancer, 15.20.4. pancreatic cancer, 15.20.5. bladder cancer 15.21. South America Gemcitabine HCL Market Attractiveness Analysis 15.21.1. By End-user 15.21.2. By Type 15.21.3. By Application 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Sun Pharmaceutical Industries 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Tapi Teva 16.3.3. Shilpa Medicare 16.3.4. Huachu Industrial 16.3.5. Jinkang Pharmaceutical Technology 16.3.6. Jierui Pharmaceutical 16.3.7. HISUN 16.3.8. Teva Pharmaceutical Industries Ltd., 16.3.9. Lupin Ltd., 16.3.10. Sanofi, 16.3.11. Biocon. 16.3.12. Dr. Reddy’s Laboratories, 16.3.13. Mylan N.V., 16.3.14. GlaxoSmithKline plc, 16.3.15. AstraZeneca plc. 16.3.16. Eli Lilly and Company 16.3.17. Pfizer Inc. 16.3.18. Cipla Inc. 16.3.19. Emcure 16.3.20. Accord Healthcare 16.3.21. Fresenius Kabi USA 17. Primary Key Insights